Quantcast

Latest Temozolomide Stories

2014-07-09 08:27:52

VANCOUVER, British Columbia and MENLO PARK, Calif., July 9, 2014 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar") announced today that the company has been awarded a non-refundable financial contribution of up to CDN$194,000 from the National Research Council of Canada's Industrial Research Assistance Program (NRC-IRAP). The research funded by this award will be conducted in collaboration with the University of British Columbia, the Vancouver Prostate Centre and...

2014-07-02 16:24:28

In this phase two study, 50 percent of glioblastoma patients lived for two years, an encouraging result for one of the most deadly cancers that often kills patients within one year of diagnosis CHICAGO, July 2, 2014 /PRNewswire-USNewswire/ -- Patients newly diagnosed with glioblastoma multiforme (GBM) and treated with an experimental cancer vaccine made from the patient's own tumor in addition to standard of care lived longer compared to those who received standard of care alone,...

2014-06-19 09:36:43

The JAMA Network Journals In patients with advanced uveal melanoma, treatment with the agent selumetinib, compared with chemotherapy, resulted in an improved cancer progression-free survival time and tumor response rate, but no improvement in overall survival, according to a study in the June 18 issue of JAMA. The modest improvement in clinical outcomes was accompanied by a high rate of adverse events. Uveal melanoma arises from melanocytes within the choroid layer of the eye. There...

2014-06-18 23:02:56

New research report “Glioblastoma Multiforme Therapeutics in Major Developed Markets to 2019 - Growth to Hinge on the Success of Personalized Vaccine Following Early Approval in Germany” elaborated by GBI Research is now available at MarketPublishers.com. According to the study, in 2019, the world GBM market value is anticipated to amount to USD 583 million. London, UK (PRWEB) June 18, 2014 Owing to the poor prognosis under presently available treatment options, therapies with high...

2014-06-17 08:29:17

SAN DIEGO, June 17, 2014 /PRNewswire/ -- DNAtrix, Inc., experts in oncolytic virus development, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track status for its lead product, DNX-2401, a replication competent adenovirus, for patients with recurrent gliobastoma. The FDA gives Fast Track status to facilitate the development of new products for serious or life-threatening conditions which demonstrate the potential to address unmet medical needs,...

2014-06-01 08:20:27

Pre-specified MGMT and HLA Subgroup Analyses Show Potentially Clinically Meaningful Survival Advantages for ICT-107 Treated Patients LOS ANGELES, June 1, 2014 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT:IMUC) announced that updated efficacy and safety data from the phase II trial of dendritic cell-based immunotherapeutic vaccine ICT-107 in patients with newly diagnosed glioblastoma multiforme (GBM) were presented at the 2014 American Society for Clinical...

2014-05-31 16:20:13

Single agent NKTR-102 exceeds primary endpoint with fifty-five percent of patients achieving six-week progression-free survival and fifteen percent of patients achieving partial response SAN FRANCISCO, May 31, 2014 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) announced today new data from an investigator-sponsored Phase 2 study of NKTR-102 (etirinotecan pegol) in patients with Avastin-refractory high-grade glioma conducted at Stanford Cancer Institute under the direction of...

2014-05-31 08:20:41

VANCOUVER, British Columbia and MENLO PARK, Calif., May 31, 2014 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar") announced the presentation of interim clinical data from the company's ongoing clinical trial with VAL-083 in refractory glioblastoma multiforme (GBM) during the Central Nervous System Tumor Session at the 50(th) Annual Meeting of the American Society of Clinical Oncology (ASCO), which is being held at the McCormick Place Convention Center in Chicago. In...

2014-05-30 08:24:56

- Results from Phase I study of investigational oncology compound ABT-414 in patients with recurrent or unresectable glioblastoma multiforme, an aggressive type of brain cancer NORTH CHICAGO, Ill., May 30, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) released preliminary results from an ongoing Phase I study with ABT-414, an anti-epidermal growth factor receptor (EGFR) monoclonal antibody drug conjugate, in combination with temozolomide, which showed four objective responses, including one...

2014-05-16 08:26:16

30mg/m2 dose cohort had been completed; enrollment of 40mg/m2 cohort has been initiated VANCOUVER, British Columbia and MENLO PARK, Calif., May 16, 2014 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar") is pleased to provide an update on the company's ongoing Phase I/II clinical trial for VAL-083 in recurrent glioblastoma multiforme (GBM). DelMar has completed enrollment of VAL-083 dose Cohort 6 and advanced to Cohort 7. DelMar most recently presented...


Word of the Day
bibliopole
  • A bookseller; now, especially, a dealer in rare and curious books.
This word comes from a Greek phrase meaning 'book seller.'
Related